His company, Berkshire Hathaway (BRKA), said Friday that its profit grew by nearly $2 billion in the second quarter.
The company, a broad-based investment conglomerate that includes diverse names like Geico Auto Insurance, Burlington Northern Santa Fe Railway, Dairy Queen, Benjamin Moore, Fruit of the Loom, Heinz, and See's Candies, earned a profit of nearly $6.4 billion, up from $4.5 billion during the same period last year.
In the first quarter, Berkshire's railroad operations took a hit from the extreme winter weather that hit much of the nation.
The kid who got the Buffett/McCartney picAs the nation's housing market has shown signs of improvement, many of the related companies that fall under Berkshire Hathaway's umbrella saw good results.
Top Value Stocks To Buy For 2015: Alamo Group Inc. (ALG)
Alamo Group, Inc. provides equipment and related replacement parts for maintenance and agriculture. It offers industrial equipment, such as boom-mounted mowers and other types of cutters for heavy-duty, intensive use applications, including maintenance around highway, airport, recreational, and other public areas; heavy-duty, tractor-and truck-mounted mowing and vegetation maintenance equipment; air, mechanical broom, and regenerative air sweepers along with environmental sweepers, and pothole patchers; and products for excavation, grading, shaping, and other tasks involved in land clearing, road building, or maintenance. The company produces catch basin cleaners and roadway debris vacuum systems; parking lot sweepers; and snow plows and heavy-duty snow removal equipment, hitches and attachments for trucks, loaders, and graders. It offers a line of tractor-powered equipment, such as rotary cutters, finishing mowers, flail mowers, disc mowers, ZTR ride-on mowers, front-end loaders, backhoes, rotary tillers, posthole diggers, and scraper blades; cutting parts, plain and hard-faced replacement tillage tools, disc blades, and fertilizer application components; heavy-duty mechanical rotary mowers, snow blowers, and rock removal equipment; a line of hydraulic, boom-mounted hedge, and grass cutters, as well as other tractor attachments and implements; and hydraulic, boom-mounted hedge and hedgerow cutters, and agricultural seedbed preparation cultivators. The company also provides light-duty power arm mowers and agricultural implements; vacuum trucks, high pressure cleaning systems, and trenchers; and hydraulic and mechanical boom mowers. The company sells its products through a network of independent dealers and distributors, governmental end-users, and related independent contractors, as well as to the agricultural and commercial turf markets in the United States, England, France, Canada, and Australia. The company was founded in 1955 and is based in Seguin, Texas.
Advisors' Opinion:- [By Garrett Cook]
In trading on Thursday, industrials shares were relative leaders, up on the day by about 0.66 percent. Top gainers in the sector included Alamo Group (NYSE: ALG), up 27.5 percent, and PMFG (NASDAQ: PMFG), up 7.8 percent.
Top Railroad Companies For 2014: United States Natural Gas Fund LP (UNG)
United States Natural Gas Fund, LP (USNG) is a limited partnership. The Company is a commodity pool that issues limited partnership interests (units) traded on the NYSE Arca, Inc. (the NYSE Arca). The investment objective of USNG is for the changes in percentage terms of its units��net asset value (NAV) to reflect the changes in percentage terms of the spot price of natural gas delivered at the Henry Hub, Louisiana as measured by the changes in the Futures Contract on natural gas traded on the New York Mercantile Exchange (NYMEX) that is the near month contract to expire, except when the near month contract is within two weeks of expiration, in which case the futures contract will be the next month contract to expire. The Company�� general partner is United States Commodity Funds LLC (the General Partner) and is responsible for the management of USNG.
USNG invests in futures contracts for natural gas, crude oil, heating oil, gasoline, and other petroleum-based fuels that are traded on the NYMEX, ICE Futures or other United States and foreign exchanges (collectively, Futures Contracts). USNG also invests in other natural gas-related investments, such as cash-settled options on Futures Contracts, forward contracts for natural gas, cleared swap contracts, and over-the-counter transactions that are based on the price of natural gas, oil and other petroleum-based fuels, Futures Contracts and indices based on the foregoing (collectively, Other Natural Gas-Related Investments). USNG invests in Natural Gas Interests to the fullest extent possible. In pursuing this objective, the primary focus of the General Partner is the investment in Futures Contracts and the management of USNG�� investments in short-term obligations of the United States of two years or less (Treasuries), cash and/or cash equivalents for margining purposes and as collateral.
Advisors' Opinion:- [By Matthew McCall]
United States Natural Gas ETF (NYSE: UNG)
The cold weather continues to grip the Northeast and natural gas prices remain high. UNG pulled back to support at the $23.50 area this week before beginning to attract buyers again. The ETF was up 2.7 percent Thursday and closed at a new one-week high as volume picked up. Technically the chart is suggesting the ETF could continue its run to the $26 area based on the recent action.
Top Railroad Companies For 2014: Barclays PLC(BCS)
Barclays PLC provides various financial products and services in Europe, the United States, Africa, and Asia. It offers retail and commercial banking, credit cards, investment banking, wealth management, and investment management services. The company?s products include current account and savings products, Woolwich branded mortgages, unsecured loans, protection products, general insurance, credit cards, Sharia-compliant products, installment finance and commercial property finance, commercial loans, and personal loans. It also offers money transmission, international and private banking, investment management, fiduciary, and brokerage services, as well as payment solutions and mobile banking services. In addition, the company provides fixed income, currency and commodities, foreign exchange, emerging markets, money markets, and credit services; equities, which include cash and equity derivatives and prime services; investment banking products and services that comprise fi nancial advisory, and equity and debt underwriting; and advisory services. It serves individual, commercial, corporate, institutional, retail, and mass affluent customers. The company was formerly known as Barclays Bank Limited and changed its name to Barclays PLC in January 1985. Barclays PLC was founded in 1896 and is headquartered in London, the United Kingdom.
Advisors' Opinion:- [By David O��ara]
LONDON -- New management at Barclays (LSE: BARC ) (NYSE: BCS ) is determined to transform the culture and practices at the bank. Unfortunately for shareholders, this posturing seems to be deflecting the market's attention from just how successful the underlying business is. This is good for contrarian investors like me. The negative sentiment has depressed Barclays' share price, presenting the opportunity to continue increasing my stake.
Top Railroad Companies For 2014: Marchex Inc.(MCHX)
Marchex, Inc. operates as a call advertising and small business marketing company. The company?s products, services, and technologies enable advertisers to reach consumers across mobile, online, and offline sources. It offers call advertising products and services to national advertisers, advertising agencies, and small advertiser reseller partners, which include pay-for-call through the Marchex Pay-For-Call Exchange and call analytics solutions comprising phone number and call tracking, call mining, keyword-level tracking, click-to-call, Website proxying, and other call-based products that enable customers to utilize mobile, online, and offline advertising. The company also offers small business marketing products that enable reseller partners of small business advertisers, such as Yellow Pages providers and vertical marketing service providers to sell call advertising and/or search marketing products through their existing sales channels, which are fulfilled across the c ompany?s distribution network, such as mobile sources, search engines, and traffic sources. In addition, it offers pay-per-click advertising to online users in response to their keyword search queries or on pages they visit throughout the company?s distribution network of search engines, shopping engines, third party verticals, local Websites, mobile distribution, and publishing network. Further, the company offers publishing network, which includes the company?s owned and operated Websites that help users to make decisions about the availability of local products and services. The Websites in the company?s publishing network include small business listings, as well as expert and user-generated reviews on small businesses. Marchex, Inc., through its products and services distributes advertisements from various advertisers and its reseller partners? advertisers. The company was founded in 2003 and is headquartered in Seattle, Washington.
Advisors' Opinion:- [By Roberto Pedone]
Marchex (MCHX) operates as a mobile and call advertising technology company in the U.S. and Canada. This stock closed up 5.8% to $4.19 in Tuesday's trading session.
Tuesday's Range: $3.94-$4.35
52-Week Range: $3.92-$12.84
Tuesday's Volume: 1.35 million
Three-Month Average Volume: 501,856From a technical perspective, MCHX ripped higher here right above its new 52-week low of $3.92 with heavy upside volume flows. This stock recently gapped down sharply from just over $7.50 to below $4 with heavy downside volume. Following that move, shares of MCHX have now started to rebound off that $3.92 low and it's quickly moving within range of triggering a major breakout trade. That trade will hit if MCHX manages to clear its gap-down-day high of $4.50 with high volume.
Traders should now look for long-biased trades in MCHX as long as it's trending above its new 52-week low of $3.92 and then once it sustains a move or close above $4.50 with volume that hits near or above 501,856 shares. If that breakout triggers soon, then MCHX will set up to re-fill some of its previous gap-down-day zone that started just above $7.50.
- [By Seth Jayson]
Marchex (Nasdaq: MCHX ) reported earnings on May 8. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Marchex beat expectations on revenues and beat expectations on earnings per share.
Top Railroad Companies For 2014: Cancer Genetics Inc (CGIX)
Cancer Genetics, Inc. (CGI), incorporated on April 8, 1999, is an early-stage, diagnostic company. The Company focuses on developing and commercializing genomic tests and services to improve the diagnosis, prognosis and response to treatment (theranosis) of cancer. These cancers include hematological, urogenital and human papillomavirus (HPV)-associated cancers. It provides its tests and services to oncologists and pathologists at hospitals, cancer centers, and physician offices. In January 2012, the Company received CLIA approval for MatBA-SLL, its microarray for risk stratification in small lymphocytic lymphoma (SLL). In February 2013, the Company received CLIA approval for MatBA-DLBCL, its microarray for diagnosis, prognosis and patient monitoring in diffuse large B cell lymphoma (DLBCL). In addition, the Company is developing a series of other genomic tests in its core oncology markets. The Company develops and produces two types of deoxyribonucleic acid (DNA)-based genomic tests: microarrays and probes.
The Company is in the final stages of validating MatBATM-SLL for risk stratification in small lymphocytic lymphoma (SLL), a subset of CLL that presents as a mass, with Memorial Sloan-Kettering Cancer Center and Long Island Jewish / North Shore Hospital. The Company is also internally clinically validating the MatBATM microarray in a variety of additional lymphoma subtypes, including mantle-cell lymphoma (MCL), follicular lymphoma (FL), and diffuses large B cell lymphoma (DLBCL). Its MatBATM array has been designed to measure genetic markers at 80 specific genomic sites where genetic alterations are associated with mature B cell neoplasms.
CGI is also developing microarray tests for the diagnosis, prognosis and theranosis of a range of urogenital cancers. These include the UroGenRA microarray for kidney, prostate and bladder cancers and the UGenRA microarray for endometrial (lining of the uterus), ovarian and cervical cancers. UroGenRA detects genomic changes in over 100 r! egions of the human genome with potential diagnostic and/or prognostic value in one or more of these types of cancer. It has initiated clinical validation for UroGenRA targeting kidney and prostate cancers in collaboration with Memorial Sloan-Kettering Cancer Center. Its UGenRA microarray has been designed as a platform to detect genomic changes occurring in 83 regions of the human genome that have been linked to endometrial, ovarian and cervical cancers In addition, it develop and manufacture a portfolio of fluorescence in situ hybridization (FISH) based DNA probes focused on blood-based and solid cancers that it sell outside the United States. The Company laboratory services include: Oncology Testing Services, which are based on its microarray tests and are available only in its clinical laboratory; Esoteric Oncology Testing Services, which it offers a suite of esoteric oncology testing services for hematological, urogenital and HPV-associated cancers, and Clinical Trial Services, which also utilize its clinical laboratory to provide clinical trial services to biopharmaceutical companies and clinical research organizations.
Hematological Cancer Arrays: MatBA-CLL/SLL, Other Mat-BA and LeukA
MatBA is an oligonucleotide-based microarray the Company developed for the analysis of genomic alterations in mature B-cell neoplasms to determine prognosis and theranosis. MatBA incorporates a common architecture of specific genomic regions that can be applied across the seven major mature B-cell neoplasms. As a group, hematologic cancers (cancers of the blood, bone marrow or lymph nodes) display clinical, pathologic and genetic complexity. Importantly, the clinical course of the six main subtypes of these neoplasms ranges from indolent (follicular lymphoma) to aggressive (diffuse large B-cell lymphoma, mantle cell lymphoma and multiple myeloma), or mixed (chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL).
MatBA is designed to detect genomic copy number chan! ges in ma! ture B-cell neoplasms. The test relies on the comparative genomic hybridization of fluorescently differentially-labeled normal DNA and DNA extracted from the cancer specimen (array-CGH). Array-CGH utilizes minimal biopsy material and uses DNA as the analyte (the component whose properties are being measured). MatBA was custom-designed to represent 80 regions of the human genome which have diagnostic and/or prognostic value in one or more of the mature B-cell neoplasm subtypes as identified through our research and analysis efforts. Unlike other technologies such as FISH, array-CGH using MatBA simultaneously permits the detection of genomic gains and losses at multiple locations on a chromosome (loci) that characterize the mature B-cell neoplasm subtypes. For each subtype of B-cell neoplasm, cohorts of specimens with full clinical annotation are evaluated using MatBA to identify associations between single and weighted combinations of genomic gains/losses and clinically relevant endpoints.
The Company offers the application of MatBA for prognostication in one subtype of mature B-cell neoplasm, CLL, where about half of patients experience indolent disease, or slow progression, and the remaining half, a relatively aggressive progression. MatBA-CLL provides genetic-based information to guide clinical management of this disease. In January 2012, MatBA-SLL was approved under CLIA and accordingly may now be offered as an LDT by its laboratory. In January 2013, this assay received approval by CLIA and New-York State for clinical use, and accordingly may now be offered as an LDT by our reference laboratory.
During the year ended December 31, 2012, the Company had similar development of MatBA as a prognostic tool in two of the other main subtypes of mature B-cell lymphomas, namely DLBCL and FL. FL is characterized by a slow progression that in up to approximately 60% of cases transforms to DLBCL, an aggressive lymphoma. Prognostic and theranostic biomarkers of therapeutic options are req! uired for! these diseases.
Urogenital cancer arrays: UroGenRA, UGenRA
The UroGenRA microarray provides diagnostic and prognostic analysis for kidney, bladder and prostate cancer. Its initial launch, UroGenRA-Kidney targets kidney cancer. It also develops extensions of UroGenRA for bladder and prostate cancers. UGenRA provide diagnostic, prognostic and theranostic information for the primary gynecological cancers, cervical, ovarian and endometrial. UroGenRA is a CGH-based array which serves as a platform for the diagnosis, prognosis and theranosis of kidney, prostate and bladder cancers. It represents 101 regions of the human genome potentially with diagnostic, prognostic and/or theranostic value in one or more of these types of cancers. UroGenRA-Kidney For kidney cancer, UroGenRA is specifically designed to classify renal tumors into the four main subtypes (clear cell, papillary, chromophobe and oncocytoma), which is critical to patient management and treatment protocols.
UroGenRA-Prostate for prostate cancer, UroGenRA use prostate core/needle biopsy to assess genomic variability of the cancer and help in the identification of biomarkers for assessment of the risk of recurrence, to assess treatment options for intermediate risk patients, and to explore the genomic aberrations of circulating tumor cells. UroGenRA-Prostate is in the commercial development stage. UroGenRA-Bladder is a diagnosed bladder cancers are defined by the fact or extent of invasion of the muscle. UroGenRA-Bladder is in the clinical development stage.
UGenRA for Endometrial, Ovarian and Cervical Cancers
UGenRA is designed as a platform to detect gains and losses of genomic material in 83 regions of the chromosome associated with responses to particular therapies in patients with endometrial, ovarian and cervical. UGenRA-Endometrial Endometrial cancer is common cancer in women in the United States. In this disease, endometrial hyperplasia is a precursor lesion of endometr! ioid endo! metrial carcinoma (EEC). UGenRA Endometrial is in the clinical development stage.
UGenRA-Ovarian is cases of ovarian cancer. UGenRA Ovarian is in the clinical development stage. As of December 31, 2012, UGenRA-Cervical was approximately 11,270 cases of cervical cancer diagnosed and approximately 4,290 deaths from cervical cancer in the United States. UGenRA Cervical is in the clinical development stage.
Advisors' Opinion:- [By RedChip]
In an amended S-1 filed with the SEC this morning, Cancer Genetics, Inc. (NASDAQ: CGIX) added two new firms to its offering syndicate and upped its capital raise 25% to $50 million. With the underwriters��overallotment, the total raise is now forecasted to reach as much as $57.5 million.
Top Railroad Companies For 2014: Inphi Corporation (IPHI)
Inphi Corporation provides high-speed analog and mixed signal semiconductor solutions for the communications, datacenter, and computing markets worldwide. Its analog and mixed signal semiconductor solutions offer high signal integrity at data speeds while reducing system power consumption. The company�s semiconductor solutions are designed to address bandwidth bottlenecks in networks, maximize throughput and minimize latency in computing environments, and enable the rollout of next generation communications, datacenter, and computing infrastructures. Its solutions provide a high-speed interface between analog signals and digital information in high-performance systems, such as telecommunications transport systems, enterprise networking equipment, datacenters and enterprise servers, storage platforms, test and measurement equipment, and military systems. The company also provides 40G and 100G high-speed analog semiconductor solutions for the communications market and high- speed memory interface solutions for the computing market. Its products include amplifiers and modulator drivers, clock and data recovery, isolation memory buffer, register, and SerDes products that perform a range of functions, such as amplifying, encoding, multiplexing, demultiplexing, retiming, and buffering data and clock signals at speeds up to 100 Gbps. Inphi Corporation sells its products directly through its sales force, as well as through a network of sales representatives and distributors to original equipment manufacturers. The company was formerly known as TCom Communications, Inc. and changed its name to Inphi Corporation in February 2001. Inphi Corporation was founded in 2000 and is headquartered in Santa Clara, California.
Advisors' Opinion:- [By Roberto Pedone]
Inphi (IPHI) provides high-speed analog and mixed signal semiconductor solutions for the communications, datacenter and computing markets. This stock closed up 4.7% at $13.25 in Monday's trading session.
Monday's Volume: 838,000
Three-Month Average Volume: 202,080
Volume % Change: 378%From a technical perspective, IPHI jumped higher here right above some near-term support at $12.44 with heavy upside volume. This stock has been uptrending strong for the last five months, with shares soaring higher from its low of $8.62 to its intraday high of $13.85. During that uptrend, shares of IPHI have been consistently making higher lows and higher highs, which is bullish technical price action. That move briefly pushed shares of IPHI into breakout territory, since the stock flirted with some near-term overhead resistance at $13.50.
Traders should now look for long-biased trades in IPHI as long as it's trending above some near-term support at $12.44 and then once it sustains a move or close above its new 52-week high at $13.85 with volume that hits near or above 202,080 shares. If we get that move soon, then IPHI will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are its next major overhead resistance levels at $14.79 to $16.94, or possibly even $18.
No comments:
Post a Comment